Lipoatrophic diabetes

Summary

Lipoatrophic diabetes (MONDO:0005827) is a disease and 2 clinical trials. Top therapeutic interventions include empagliflozin. A subtype of type 2 diabetes mellitus — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lipoatrophic diabetes
Mondo ID	MONDO:0005827
EFO	EFO:0007346
MeSH	D003923
DOID	DOID:11712
NCIT	C34537
SNOMED CT	127012008
UMLS	C0011859
MedGen	4256
Is cancer (heuristic)	no

Also known as: diabete, lipoatrophic · diabetes, lipoatrophic · lipoatrophic diabete · lipoatrophic diabetes · lipoatrophic diabetes mellitus

Disease family

This is a subtype of type 2 diabetes mellitus. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › pancreas disorder › endocrine pancreas disorder › diabetes mellitus › type 2 diabetes mellitus › lipoatrophic diabetes

Related subtypes (5): diabetes mellitus, noninsulin-dependent, 1, diabetes mellitus, noninsulin-dependent, 2, diabetes mellitus, noninsulin-dependent, 3, diabetes mellitus, noninsulin-dependent, 4, diabetes mellitus, noninsulin-dependent, 5

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04018365	PHASE3	UNKNOWN	A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance
NCT04221152	PHASE3	UNKNOWN	A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EMPAGLIFLOZIN	4	2